Management Comment
AnPac Bio’s CEO, Dr. Chris Yu, commented, “In addition to a successful launch of our immunology test product in the first half year, the qualification and commercialization of COVID-19 tests is another major achievement for AnPac Bio this year. With the addition of above mentioned new products and services, and our novel, biophysics based cancer differentiation analysis (CDA) cancer screening tests, AnPac Bio is poised to offer our customers and market a much broader set of products and services and will contribute to our revenue growth significantly in the next few years”.